1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Pharma Mar,S.A.
  6. Summary
    PHM   ES0169501022

PHARMA MAR,S.A.

(PHM)
  Report
Delayed Quote. Delayed Bolsas y Mercados Espanoles - 05/16 11:38:00 am
70.48 EUR   +1.64%
04/29TRANSCRIPT : Pharma Mar, S.A., Q1 2022 Earnings Call, Apr 29, 2022
CI
04/28PHARMA MAR,S.A. : 1st quarter results
CO
03/09TRANSCRIPT : Pharma Mar, S.A. - Special Call
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
67.18(c) 68.34(c) 67.24(c) 69.34(c) 70.48 Last
80 153 44 142 57 490 40 790 37 805 Volume
-0.53% +1.73% -1.61% +3.12% +1.64% Change
More quotes
Estimated financial data (e)
Sales 2022 220 M 229 M 229 M
Net income 2022 79,0 M 82,2 M 82,2 M
Net cash position 2022 217 M 225 M 225 M
P/E ratio 2022 16,1x
Yield 2022 0,80%
Sales 2023 259 M 269 M 269 M
Net income 2023 116 M 120 M 120 M
Net cash position 2023 302 M 315 M 315 M
P/E ratio 2023 11,5x
Yield 2023 0,75%
Capitalization 1 269 M 1 321 M 1 321 M
EV / Sales 2022 4,78x
EV / Sales 2023 3,74x
Nbr of Employees 477
Free-Float 71,8%
More Financials
Company
Pharma Mar, S.A. specializes in research and development into marine-origin medicines. The group also offers tools to treat cancer. Net sales break down by family of products as follows: - antitumor drugs (93.3%). Pharma Mar also offers medicines for the treatment of immune and viral diseases. At the end of 2019, the group had a portfolio of 6 products in clinical development phase (including 1 in phase III, 2 in... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Ratings of Pharma Mar,S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about PHARMA MAR,S.A.
04/29TRANSCRIPT : Pharma Mar, S.A., Q1 2022 Earnings Call, Apr 29, 2022
CI
04/28PHARMA MAR,S.A. : 1st quarter results
CO
03/09TRANSCRIPT : Pharma Mar, S.A. - Special Call
CI
03/07PharmaMar receives the first commercial milestone payment from Jazz Pharmaceuticals for..
AQ
03/01TRANSCRIPT : Pharma Mar, S.A., 2021 Earnings Call, Mar 01, 2022
CI
02/28Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/28PHARMA MAR S A : Annual Report PharmaMar 2021
PU
02/28PHARMA MAR S A : Separate Financial Statements 2021
PU
02/28PHARMA MAR S A : Non-financial Information Statement 2021
PU
02/28Spain's PharmaMar raises dividend despite 32% drop in 2021 profit
RE
02/28Spain's PharmaMar 2021 net profit falls 32%
RE
01/12Life Science Alliance journal publishes results of plitidepsin in patients with COVID-1..
AQ
01/11Pharma Mar, S.A. Announces Publication of an Article in the Life Science Alliance Journ..
CI
01/11PharmaMar shares soar after drug study suggests efficacy against Omicron
RE
01/11Pharma Mar Surges 9% as COVID-19 Treatment Shows Efficacy Against Omicron
MT
More news
News in other languages on PHARMA MAR,S.A.
04/29EN DIRECTO DESDE LOS MERCADOS : Merlin, BBVA, Indra, Pharma, CaixaBank, Apple, Amazon, Twi..
04/29BOLSA DE MADRID : ┐China como apoyo?
04/04BOLSA DE MADRID : "Nuestras materias primas, vuestro problema"
03/04EN DIRECTO DESDE LOS MERCADOS : ArcelorMittal, Cellnex, Telefónica, Honda, BBVA, Crédit Su..
03/04BOLSA DE MADRID : Terror nuclear
More news
Analyst Recommendations on PHARMA MAR,S.A.
More recommendations
Chart PHARMA MAR,S.A.
Duration : Period :
Pharma Mar,S.A. Technical Analysis Chart | PHM | ES0169501022 | MarketScreener
Technical analysis trends PHARMA MAR,S.A.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 69,34 €
Average target price 79,42 €
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
JosÚ Maria Fernßndez de Sousa-Faro Executive Chairman, President & CEO
Maria Luisa de Francia Caballero Chief Financial Officer
Nadia Badri Vice President-Medical Affairs
Carmen Cuevas Marchante Director-Research & Development
Luis RupÚrez Cuenca Director-Human Resources & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
PHARMA MAR,S.A.21.61%1 300
CSL LIMITED-3.62%93 394
SAMSUNG BIOLOGICS CO.,LTD.-14.73%43 585
BIOGEN INC.-17.01%29 160
WUXI BIOLOGICS (CAYMAN) INC.-43.92%27 891
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.41%23 276